NRX Pharmaceuticals Inc (NRXP)

Currency in USD
2.630
-0.060(-2.23%)
Closed·
2.730+0.100(+3.80%)
·
NRXP Scorecard
Full Analysis
Net income is expected to grow this year
Unusual trading volume
NRXP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.5802.830
52 wk Range
1.1006.010
Key Statistics
Prev. Close
2.69
Open
2.78
Day's Range
2.58-2.83
52 wk Range
1.1-6.01
Volume
783.51K
Average Volume (3m)
287.15K
1-Year Change
39.15%
Book Value / Share
-1.83
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NRXP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.667
Upside
+1,180.10%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

NRX Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

NRX Pharmaceuticals Inc Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.

NRX Pharmaceuticals Inc Earnings Call Summary for Q2/2025

  • NRX Pharmaceuticals reported Q2 2025 EPS of -$0.98, missing forecast of -$0.53; stock fell 9.24% to $2.505 post-announcement
  • Net loss widened to $17.5 million from $7.9 million in Q2 2024; company raised $6.5 million through registered direct offering
  • Focus on regulatory approval for NRx100 and NRx101 treatments; targeting $750 million ketamine market and 7 million bipolar depression patients
  • CEO optimistic about future, emphasizing neuroplasticity treatments; company developing national network of mental health centers
  • Analysts forecast profitability this year with EPS of $0.2; future EPS and revenue expected to improve in FY 2025 and FY 2026
Last Updated: 20/08/2025, 14:14
Read Full Transcript

Compare NRXP to Peers and Sector

Metrics to compare
NRXP
Peers
Sector
Relationship
P/E Ratio
−1.8x−0.5x−0.5x
PEG Ratio
−0.120.090.00
Price/Book
−1.8x2.3x2.6x
Price / LTM Sales
-1.8x3.3x
Upside (Analyst Target)
-154.9%38.7%
Fair Value Upside
Unlock9.8%5.0%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 33.667
(+1,180.10% Upside)

Earnings

Latest Release
Aug 18, 2025
EPS / Forecast
-0.98 / -0.53
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NRXP Income Statement

People Also Watch

18.26
SRPT
+1.11%
6.50
LFMD
+5.01%
5.350
BBAI
+0.94%
5.68
REPL
+3.46%
57.45
BMRN
-1.79%

FAQ

What Stock Exchange Does NRX Pharmaceuticals Trade On?

NRX Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for NRX Pharmaceuticals?

The stock symbol for NRX Pharmaceuticals is "NRXP."

What Is the NRX Pharmaceuticals Market Cap?

As of today, NRX Pharmaceuticals market cap is 51.00M.

What Is NRX Pharmaceuticals's Earnings Per Share (TTM)?

The NRX Pharmaceuticals EPS (TTM) is -2.35.

From a Technical Analysis Perspective, Is NRXP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has NRX Pharmaceuticals Stock Split?

NRX Pharmaceuticals has split 1 times.

How Many Employees Does NRX Pharmaceuticals Have?

NRX Pharmaceuticals has 0 employees.

What is the current trading status of NRX Pharmaceuticals (NRXP)?

As of 27 Aug 2025, NRX Pharmaceuticals (NRXP) is trading at a price of 2.63, with a previous close of 2.69. The stock has fluctuated within a day range of 2.58 to 2.83, while its 52-week range spans from 1.10 to 6.01.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.